HDAC-selective Inhibitor Cay10603 Has Single Anti-tumour Effect in Burkitt's Lymphoma Cells by Impeding the Cell Cycle.
Curr Med Sci
; 39(2): 228-236, 2019 Apr.
Article
in En
| MEDLINE
| ID: mdl-31016515
ABSTRACT
Histone deacetylases (HDACs) inhibitors are novel in cancer therapy nowadays. HDAC6-selective inhibitors exert advantageous effects due to higher selectivity and less toxicity. We explored the anti-tumor effect and the molecular mechanism of cay10603, a potent HDAC6 inhibitor in Burkitt's lymphoma cells. Our study revealed cay10603 inhibited the proliferation of Burkitt's lymphoma cell lines, and induced caspase-dependent apoptosis. Cay10603 inhibited the expression of CDKs and cyclins to impede cell cycle progression in both Burkitt's lymphoma cell lines. Cay10603 also showed the additive effect with vp16 notably. Our data presented the promising anti-tumor effect of cay10603 in the Burkitt's lymphoma therapy.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Cell Cycle
/
Burkitt Lymphoma
/
Histone Deacetylase Inhibitors
/
Histone Deacetylases
/
Antineoplastic Agents
Limits:
Humans
Language:
En
Journal:
Curr Med Sci
Year:
2019
Document type:
Article
Affiliation country:
China